I'll keep this short and sweet...Google "PennyStock101' signup for their free newsletter and get their next trade alert. Come back and thank me tomorrow!
Could anyone tell me how the J-code rebate requirements might effect ALIM's "Accounts Receivable"?
We know that once the company acquires the coding, many, many more doctors will want to start using it since it can be simplified for insurance company and government program reimbursing.
And what are the risks involved with the legislation being proposed to put a ceiling on what drug manufactures can charge?
They are already obviously utilizing "their" sales force and marketing strategies, but are still in the founding process. This is why you see a 188% over 3rd period in '14.
Once they achieve their J-code insurance listing and reimbursements truly begin on $9.377 MILLION, you are going to see this stock explode. I'm glad I am here on the ground floor with you..
I know it's a lump to swallow, I do agree with you, the pay seems extravagant, but we are talking the edge of medical science here, so I'm glad to have every one of them compensated. They are building a company here that is either going to explode, or be a buy-out target.
I tend to lean toward the buy-out, because we are talking about a whole lot of money behind this science they're behind.
You'll DEFINITELY see a tremendous boost for this company after the first of the year with the J-code making it easy for physicians and medical facilities to file their costs to insurance companies.
Looks to me like everything is absolutely "on track". Once they get their J-code making it easy for doctors to file for insurance companies, this stock is going to explode with almost $9.4 MILLION accounts receivable. (These aren't "questionable accounts -- they are from physicians and medical providers -- they are solid.)
Deerfield made a significant buy of xnpt also, my thoughts, since I hold xnpt, are that they see both alim and xnpt as real buyout candidates before the end of the year. Each is sitting on a single product that has potential to be much greater than what xnpt and alim have been able to get going on them. Someone with a large salesforce in place could quickly advance sales of either.
It must be expensive to have 31 sales reps on there pay list before handling the reimbursement issue. I don't get how they can be surprised about the importance of this issue (as told at the Conference Call).... Have they never heard about e.g. a company like Dendreon and there challenges bringing an expensive product to marked without handling the reimbursemt issue?? Actually Dendreon filed Chapter 11 on this matter for one year ago. I wonder how they can be so surprised about this... :-(
As I heard it at the Conference Call they now expect to reach break even in the second part of 2016 or 2017...( and not in the first part of 2016) And Also that even though the Jcode will be available from 2016.01.10 it does not mean that we will se the full effect of this in the first quarters of 2016 ( the QA session part of the CC) I don't expect any miracles in the short term regarding the sale of Illuvein, unfortunately.
I'm long Alimera and the J Code is going to help sales. But, what the heck.....can these guys spend
money ? How do you spend 7.5 million on R&D and administrative in a quarter? I say someone's making a good living here and it isn't the stockholder yet.
I think you're going to be surprised. Once they get a "J" code, they will reach an unprecedented growth record for the first and second quarters.
As you know, the slow ramp has been known since the summer. Obviously they do not have a positive cash yet and could not meet the current repayment schedule, but notice that the end date has NOT been shifted in the new conditions. Everyone gets a little something out of this deal. It might seem negative today, but I think we are going to find out in the near future that everything is on track to enable a big ramp in Q1. Who knows, they might have a few positive surprises this week after what is perceived to be negative news today.
Yep - but, will they be able to achieve this in the first half of 2016 as previously announced. I doubt it
Sentiment: Strong Buy
The ramp is definitely not as planned and therefore they tripped a loan covenant so the loan deal had to be re-negotiated. It's looks like they expect to have the positive cash flow going forward in 2016 and 2017 though.
Anyone think the adjusted financing was done so they do not need to dilute before becoming profitable? It allows ALIM to concentrate all resources into growing sales with no new funds required.